logo
logo
logo
logo
Kashvi Banerjee 2021-08-06
img

The global Epinephrine Autoinjector Market report offers a comprehensive assessment of the market for the forecast years.

This globe industry offers an outlook on the strategic development of the market in terms of revenue profits over the forecast period 2021-2026.The key market players for the global Epinephrine Autoinjector market are listed below:MylanImpaxSanofiALK AbelloOthersClick here to get a FREE Sample Copy of the Epinephrine Autoinjector Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-26867The Global Epinephrine Autoinjector Market Report is equipped with market data from 2016 to 2026.

It also evaluates the competitive scenario of the leading players.

The report forecasts sales and revenue from 2021 to 2026.

The detailed sales channel is also covered in the study.COVID-19 Impact Analysis on Epinephrine Autoinjector MarketThe global pandemic COVID-19 has affected the Epinephrine Autoinjector market directly or indirectly.

The impact study on production, supply-demand, and sales provides a holistic approach to the future.Do You Have Any Query Or Report Customization?

collect
1
shikha sharma 2020-07-15
img

The Latest Trending Report Global Epinephrine Autoinjector Market 2020 By Manufacturers, Regions, Type And Application, Forecast To 2025 Offered By Decisiondatabases.Com Is An Informative Study Covering The Market With Detailed Analysis.

The Report Will Assist Reader With Better Understanding And Decision Making.The global Epinephrine Autoinjector market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.7% in the forecast period of 2020 to 2025 and will expected to reach USD 2504.4 million by 2025, from USD 1932.2 million in 2019.The Epinephrine Autoinjector market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/26867-epinephrine-autoinjector-market-analysis-reportThe major players covered in Epinephrine Autoinjector are:MylanImpaxSanofiALK AbelloBy Type, Epinephrine Autoinjector market has been segmented into :0.30 mg0.15 mgBy Application, Epinephrine Autoinjector has been segmented into :Under 6 years6 to 12 yearsOver 12 yearsThe report offers in-depth assessment of the growth and other aspects of the Epinephrine Autoinjector market in important countries (regions), including:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, etc.

)Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Epinephrine Autoinjector Market @ https://www.decisiondatabases.com/contact/download-sample-26867The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Epinephrine Autoinjector product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Epinephrine Autoinjector, with price, sales, revenue and global market share of Epinephrine Autoinjector in 2018 and 2019.Chapter 3, the Epinephrine Autoinjector competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Epinephrine Autoinjector breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Epinephrine Autoinjector market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Epinephrine Autoinjector sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Epinephrine Autoinjector Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-26867Other Reports by DecisionDatabases.com:Global Microinjector Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global On-body Injectors Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Large Volume Wearable Injectors Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.

DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.

We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/

collect
0
Reportsinsightsa 2021-05-18

Global Epinephrine Autoinjector market Size by Type, End User and Application: Global Opportunity Analysis and Industry Forecast, 2020-2025.

Report Summary Epinephrine is the only treatment for a severe allergic reaction known as anaphylaxis (anna-fih-LACK-sis).

Epinephrine auto-injector is an emergency injection (shot) of epinephrine.

It is used against life-threatening allergic reactions such as severe swelling, breathing problems, or loss of blood pressure.

In the last several years, the development of Epinephrine Autoinjector industry is relative high with average production growth rate of 14.66%.

Several different factors, for example, supply chain, downstream purchasers, and sourcing methodology have been evaluated to give a top to bottom perspective on the market.

collect
0
Ronald Gibson 2016-08-24
img

If you carry an EpiPen in case of a deadly allergic reaction, you ve probably noticed the price skyrocket over the last decade.

The injectors now cost over $600 and still expire after a year, so it may be tempting to carry an expired EpiPen, or none at all.

There s an alternative, though: the Adrenaclick is a different device that delivers the same drug.

According to GoodRx, a two-pack of Adrenaclick injectors costs as little as $142 with a free coupon.

That s still not cheap, but it helps.

Since the devices are different, your pharmacist can t just substitute Adrenaclick if your prescription says EpiPen, so you ll need to ask your doctor to prescribe the one you want.

collect
0
Tom Brown 2016-09-07
img

On Wednesday, the Senate s permanent subcommittee on investigations announced it was launching a probe into the pricing of Mylan s EpiPen, the life-saving allergy treatment device which cost about $57 in 2007 and is priced at around $600 today.

Our review of this matter will be robust, thorough, and bipartisan, said the panel in a statement.

Republican and Democrat Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan s sustained price increases.

The committee described the probe as a preliminary inquiry and said it would focus on Mylan Pharmaceuticals pricing and competition practices with respect to the EpiPen.

Wednesday s announcement is just the latest headache for the pharmaceutical company since the price changes began receiving mainstream press coverage last month.

In August, the Congressional House Oversight Committee sent Mylan a letter requesting a wide range of financial information and internal documents relating to their virtual monopoly on the product.

collect
0
Tom Snipes 2016-09-02
img

If you ve got a severe allergy to something, chances are high you ve got to carry around an EpiPen with you.

These are devices that inject precise doses of adrenalin, stopping the effects of anaphylaxis in their tracks.

At $100, they were already damn expensive.

But then the manufacturer, Mylan, raised the prices to $600.

Naturally, this has been controversial, and many have compared its CEO, Heather Bresch, to the odious pharma-bro Martin Shkreli.

Now, this saga is being parodied in a free, browser-based game called what else?

collect
0
Eric Spilde 2016-12-21
img

If you have allergies and need to carry an epinephrine injector, you know that brand name EpiPens are crazy expensive: $600 or more for a two-pack.

After an outcry and Congressional hearing , EpiPen maker Mylan finally launched a generic this week.

According to the company, the list price for a two-pack will be $300.

That brings it into the same price range as Adrenaclick, currently $200 to $300 depending on your pharmacy.

If you re just looking for the cheapest option, make sure to compare prices: the Adrenaclick may still be your best bet.

The two devices deliver the same medication, but their instructions are a little bit different—Adrenaclick has two caps to remove, for example, while EpiPen and its generic only have one.

collect
0
Bradley James 2017-01-12
img

CVS announced today their generic version of the EpiPen, which is available at the pharmacy for $109.99 for a two-pack.

This is even cheaper than the other generic option, which costs $300 for a two-pack.

The CVS version is identical to Adrenaclick, and is approved by the FDA.

CVS is also introducing a coupon program for anyone who can t afford the cost.

Both the Adrenaclick and EpiPen will still be available, though the CVS version is identical in every way to Adrenaclick, so there s not much reason to shell out the extra cash unless your doctor or insurance require it.

The more affordable EpiPen alternative CVS

collect
0
Felton Woodall 2016-05-25

All four of these smart items have either been announced by startups or are already shipping.

A subset of startups inventing the world s first connected insert any noun here believe everything goes better with Bluetooth.

A connected pill bottle for seniors or an EpiPen case that sends an alert when someone goes into anaphylactic shock may save lives.

Until the hardware improves and the ideas get more practical, it is buyer beware.

Most of the companies explained the reasons for the glitches—and that, with just a handful of employees and relatively limited funding, they were working on fixes.

It aims to minimize menstruation leaks and the risk of toxic shock syndrome, an illness that can be caused by keeping in a tampon for too long.

collect
0
Jeanette Perea 2017-01-11
img

President-elect Donald Trump went after drug makers and sent biotech stocks plummeting after calling the drug industry disastrous during his first press conference since the election.

We have to create new bidding procedures for the drug industry, because they re getting away with murder, pharma, Trump said.

Pharma has a lot of lobbies, a lot of lobbyists, a lot of power.

The pledge to overhaul Big Pharma isn t exactly a new one.

During his campaign, Trump promised to crack down on high drug prices and endorsed the idea of having Medicare negotiate drug pricing—a position that has in the past garnered Democratic support and Republican opposition.

After Trump s remarks, the Nasdaq Biotechnology Index fell by more than 3 percent.

collect
0
Marc Anderson 2016-08-25

MoreEpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S., August 24, 2016.

By Ransdell Pierson and Ankur Banerjee

Reuters - Mylan NV said on Thursday it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount programme, a day after Democratic Presidential candidate Hillary Clinton joined lawmakers in criticizing the drug's high price.

However, he added, "discounts for selected customers without lowering the overall price of EpiPens are insufficient, because the excessive price will likely be passed on through higher insurance premiums."

Clinton's view was echoed by Democratic lawmakers, including Rep. Elijah Cummings, who said Mylan's move is nothing but a public relations stunt that does nothing to help the majority of patients who need the drug.

Mylan Chief Executive Heather Bresch, defending EpiPen's price in an interview on Thursday on CNBC, said her company had spent hundreds of millions of dollars improving EpiPen, including making its needle invisible, since acquiring the device from German generic drugmaker Merck KGaA.

collect
0
Thomas Brazier 2016-08-25
img

Sarah Jessica Parker has cut ties with Mylan, the company that makes EpiPen, after it was criticized for raising the price of the life-saving allergy product by 400 percent.

I m left disappointed, saddened and deeply concerned by Mylan s actions, Parker wrote on Instagram.

I do not condone this decision and I have ended my relationship with Mylan as a direct result of it.

Sarah Jessica Parker became a paid spokesperson for Mylan in May of this year and spoke about her son s life-threatening allergy on behalf of Mylan s Anaphylaxis for Reel campaign.

Parker appeared on TV shows like The View, The Doctors, and Access Hollywood to talk about her son s peanut allergy.

Gizmodo was the first to report on Tuesday that Parker s role as a paid spokesperson for Mylan didn t always include a disclaimer that she was speaking on behalf of the company.

collect
0
John Feeney 2016-08-20
img

The extensive price hike for a vital, life-saving drug for many with allergies is causing concern among doctors, patients, and politicians—along with a guy responsible for an extensive price hike himself.

Mylan pharmaceutical, the maker of the EpiPen—a portable epinephrine injector that can potentially save someone having a life-threatening allergic reaction—is being accused of raising the price of the product from around $100 in 2008 to $500 today.

In all, that s an increase of over 400 percent.

This is especially worrying because Mylan has a near monopoly in the business, especially after one of its competitors issued a recall last year.

Many schools have emergency epinephrine in stock and there are states pushing for legislation to make that mandatory.

The increase is so high that Pharma Bro and person that hates Gawker Martin Shkreli, who for months was the most hated person on the internet after his company, Turing Pharmaceuticals, acquired a 62-year-old anti-parasitic drug and jacked the price from $13.50 a pill to $750, spoke out against the move.

collect
0
Eric Erikson 2016-10-28
img

Pharmaceutical company Kaléo will offer up an alternative epinephrine auto-injector to Mylan s EpiPen starting in 2017, the company announced this week.

Though Auvi-Q s 2017 price has yet to be set, Kaléo s drug-pricing track record is similar to Mylan s. In the past few years, Kaléo has increased the price of a device used to reverse deadly opioid overdoses by more than 650 percent, in fact.

And, just like Mylan, Turing, and others, Kaléo claimed that costumer assistance programs and discounts would keep high list prices from affecting patients—even though those high list prices can still help drive up overall costs of healthcare.

In an e-mail exchange with Ars, Mark Herzog, vice president of corporate affairs for Kaléo, would not answer direct questions about whether the company would help bring down the inflated costs of epinephrine auto-injectors.

Instead, Herzog noted that the company is working to engage with various stakeholders, including wholesalers, insurance companies, and pharmacy benefit managers, to implement a comprehensive access program for Auvi-Q.

The company s intention, he added, is that any patient who needs an epinephrine auto-injector, regardless of insurance coverage, should have affordable access to Auvi-Q.

collect
0
Keith Maldonado 2017-05-31
img

p A group of disgruntled Mylan investors launched a campaign late Tuesday to block the re-election of six directors over their exorbitant—and increasing—compensation.

In a letter sent to fellow shareholders, the group lambasted hefty bonuses and salary increases that came as the company faced backlash for the skyrocketing price of its life-saving EpiPen devices.

Such outrage is likely to continue given that a new government report released today suggests that Mylan overcharged taxpayers $1.27 billion dollars for EpiPens over 10 years.

The ongoing EpiPen pricing scandal has caused Mylan "significant reputational and financial harm," the investors complained.

Yet directors continued to be rewarded.

The investors were particularly critical of Chairman Robert Coury, who received more than $160 million in compensation in 2016 and will receive a $1.8 million per year “cash retainer” as part of a deal made with Mylan last year.

collect
0
Trisha Lewis 2016-08-29
img

Netherlands-based pharmaceutical company Mylan has announced plans to launch its first generic EpiPen.

But at a cost of $300—which is half of the branded product s list price—it s still a heap of money for this critically important medicine.

Mylan is taking a lot of heat these days for boosting the price of its EpiPen by more than 400 percent.

Just eight years ago the auto-injection epinephrine pens, which are used to stave off the effects of potentially life-threatening allergic reactions, were priced at just $100 per pack.

Today the branded product costs about $600.

The company has subsequently been accused of price gouging, attracting the ire of consumers, lawmakers, doctors, and at least one disgruntled celebrity endorser.

collect
0
Kashvi Banerjee 2021-08-06
img

The global Epinephrine Autoinjector Market report offers a comprehensive assessment of the market for the forecast years.

This globe industry offers an outlook on the strategic development of the market in terms of revenue profits over the forecast period 2021-2026.The key market players for the global Epinephrine Autoinjector market are listed below:MylanImpaxSanofiALK AbelloOthersClick here to get a FREE Sample Copy of the Epinephrine Autoinjector Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-26867The Global Epinephrine Autoinjector Market Report is equipped with market data from 2016 to 2026.

It also evaluates the competitive scenario of the leading players.

The report forecasts sales and revenue from 2021 to 2026.

The detailed sales channel is also covered in the study.COVID-19 Impact Analysis on Epinephrine Autoinjector MarketThe global pandemic COVID-19 has affected the Epinephrine Autoinjector market directly or indirectly.

The impact study on production, supply-demand, and sales provides a holistic approach to the future.Do You Have Any Query Or Report Customization?

Reportsinsightsa 2021-05-18

Global Epinephrine Autoinjector market Size by Type, End User and Application: Global Opportunity Analysis and Industry Forecast, 2020-2025.

Report Summary Epinephrine is the only treatment for a severe allergic reaction known as anaphylaxis (anna-fih-LACK-sis).

Epinephrine auto-injector is an emergency injection (shot) of epinephrine.

It is used against life-threatening allergic reactions such as severe swelling, breathing problems, or loss of blood pressure.

In the last several years, the development of Epinephrine Autoinjector industry is relative high with average production growth rate of 14.66%.

Several different factors, for example, supply chain, downstream purchasers, and sourcing methodology have been evaluated to give a top to bottom perspective on the market.

Tom Brown 2016-09-07
img

On Wednesday, the Senate s permanent subcommittee on investigations announced it was launching a probe into the pricing of Mylan s EpiPen, the life-saving allergy treatment device which cost about $57 in 2007 and is priced at around $600 today.

Our review of this matter will be robust, thorough, and bipartisan, said the panel in a statement.

Republican and Democrat Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan s sustained price increases.

The committee described the probe as a preliminary inquiry and said it would focus on Mylan Pharmaceuticals pricing and competition practices with respect to the EpiPen.

Wednesday s announcement is just the latest headache for the pharmaceutical company since the price changes began receiving mainstream press coverage last month.

In August, the Congressional House Oversight Committee sent Mylan a letter requesting a wide range of financial information and internal documents relating to their virtual monopoly on the product.

Eric Spilde 2016-12-21
img

If you have allergies and need to carry an epinephrine injector, you know that brand name EpiPens are crazy expensive: $600 or more for a two-pack.

After an outcry and Congressional hearing , EpiPen maker Mylan finally launched a generic this week.

According to the company, the list price for a two-pack will be $300.

That brings it into the same price range as Adrenaclick, currently $200 to $300 depending on your pharmacy.

If you re just looking for the cheapest option, make sure to compare prices: the Adrenaclick may still be your best bet.

The two devices deliver the same medication, but their instructions are a little bit different—Adrenaclick has two caps to remove, for example, while EpiPen and its generic only have one.

Felton Woodall 2016-05-25

All four of these smart items have either been announced by startups or are already shipping.

A subset of startups inventing the world s first connected insert any noun here believe everything goes better with Bluetooth.

A connected pill bottle for seniors or an EpiPen case that sends an alert when someone goes into anaphylactic shock may save lives.

Until the hardware improves and the ideas get more practical, it is buyer beware.

Most of the companies explained the reasons for the glitches—and that, with just a handful of employees and relatively limited funding, they were working on fixes.

It aims to minimize menstruation leaks and the risk of toxic shock syndrome, an illness that can be caused by keeping in a tampon for too long.

Marc Anderson 2016-08-25

MoreEpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S., August 24, 2016.

By Ransdell Pierson and Ankur Banerjee

Reuters - Mylan NV said on Thursday it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount programme, a day after Democratic Presidential candidate Hillary Clinton joined lawmakers in criticizing the drug's high price.

However, he added, "discounts for selected customers without lowering the overall price of EpiPens are insufficient, because the excessive price will likely be passed on through higher insurance premiums."

Clinton's view was echoed by Democratic lawmakers, including Rep. Elijah Cummings, who said Mylan's move is nothing but a public relations stunt that does nothing to help the majority of patients who need the drug.

Mylan Chief Executive Heather Bresch, defending EpiPen's price in an interview on Thursday on CNBC, said her company had spent hundreds of millions of dollars improving EpiPen, including making its needle invisible, since acquiring the device from German generic drugmaker Merck KGaA.

John Feeney 2016-08-20
img

The extensive price hike for a vital, life-saving drug for many with allergies is causing concern among doctors, patients, and politicians—along with a guy responsible for an extensive price hike himself.

Mylan pharmaceutical, the maker of the EpiPen—a portable epinephrine injector that can potentially save someone having a life-threatening allergic reaction—is being accused of raising the price of the product from around $100 in 2008 to $500 today.

In all, that s an increase of over 400 percent.

This is especially worrying because Mylan has a near monopoly in the business, especially after one of its competitors issued a recall last year.

Many schools have emergency epinephrine in stock and there are states pushing for legislation to make that mandatory.

The increase is so high that Pharma Bro and person that hates Gawker Martin Shkreli, who for months was the most hated person on the internet after his company, Turing Pharmaceuticals, acquired a 62-year-old anti-parasitic drug and jacked the price from $13.50 a pill to $750, spoke out against the move.

Keith Maldonado 2017-05-31
img

p A group of disgruntled Mylan investors launched a campaign late Tuesday to block the re-election of six directors over their exorbitant—and increasing—compensation.

In a letter sent to fellow shareholders, the group lambasted hefty bonuses and salary increases that came as the company faced backlash for the skyrocketing price of its life-saving EpiPen devices.

Such outrage is likely to continue given that a new government report released today suggests that Mylan overcharged taxpayers $1.27 billion dollars for EpiPens over 10 years.

The ongoing EpiPen pricing scandal has caused Mylan "significant reputational and financial harm," the investors complained.

Yet directors continued to be rewarded.

The investors were particularly critical of Chairman Robert Coury, who received more than $160 million in compensation in 2016 and will receive a $1.8 million per year “cash retainer” as part of a deal made with Mylan last year.

shikha sharma 2020-07-15
img

The Latest Trending Report Global Epinephrine Autoinjector Market 2020 By Manufacturers, Regions, Type And Application, Forecast To 2025 Offered By Decisiondatabases.Com Is An Informative Study Covering The Market With Detailed Analysis.

The Report Will Assist Reader With Better Understanding And Decision Making.The global Epinephrine Autoinjector market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.7% in the forecast period of 2020 to 2025 and will expected to reach USD 2504.4 million by 2025, from USD 1932.2 million in 2019.The Epinephrine Autoinjector market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/26867-epinephrine-autoinjector-market-analysis-reportThe major players covered in Epinephrine Autoinjector are:MylanImpaxSanofiALK AbelloBy Type, Epinephrine Autoinjector market has been segmented into :0.30 mg0.15 mgBy Application, Epinephrine Autoinjector has been segmented into :Under 6 years6 to 12 yearsOver 12 yearsThe report offers in-depth assessment of the growth and other aspects of the Epinephrine Autoinjector market in important countries (regions), including:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, etc.

)Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Epinephrine Autoinjector Market @ https://www.decisiondatabases.com/contact/download-sample-26867The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Epinephrine Autoinjector product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Epinephrine Autoinjector, with price, sales, revenue and global market share of Epinephrine Autoinjector in 2018 and 2019.Chapter 3, the Epinephrine Autoinjector competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Epinephrine Autoinjector breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Epinephrine Autoinjector market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Epinephrine Autoinjector sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Epinephrine Autoinjector Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-26867Other Reports by DecisionDatabases.com:Global Microinjector Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global On-body Injectors Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Large Volume Wearable Injectors Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.

DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.

We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/

Ronald Gibson 2016-08-24
img

If you carry an EpiPen in case of a deadly allergic reaction, you ve probably noticed the price skyrocket over the last decade.

The injectors now cost over $600 and still expire after a year, so it may be tempting to carry an expired EpiPen, or none at all.

There s an alternative, though: the Adrenaclick is a different device that delivers the same drug.

According to GoodRx, a two-pack of Adrenaclick injectors costs as little as $142 with a free coupon.

That s still not cheap, but it helps.

Since the devices are different, your pharmacist can t just substitute Adrenaclick if your prescription says EpiPen, so you ll need to ask your doctor to prescribe the one you want.

Tom Snipes 2016-09-02
img

If you ve got a severe allergy to something, chances are high you ve got to carry around an EpiPen with you.

These are devices that inject precise doses of adrenalin, stopping the effects of anaphylaxis in their tracks.

At $100, they were already damn expensive.

But then the manufacturer, Mylan, raised the prices to $600.

Naturally, this has been controversial, and many have compared its CEO, Heather Bresch, to the odious pharma-bro Martin Shkreli.

Now, this saga is being parodied in a free, browser-based game called what else?

Bradley James 2017-01-12
img

CVS announced today their generic version of the EpiPen, which is available at the pharmacy for $109.99 for a two-pack.

This is even cheaper than the other generic option, which costs $300 for a two-pack.

The CVS version is identical to Adrenaclick, and is approved by the FDA.

CVS is also introducing a coupon program for anyone who can t afford the cost.

Both the Adrenaclick and EpiPen will still be available, though the CVS version is identical in every way to Adrenaclick, so there s not much reason to shell out the extra cash unless your doctor or insurance require it.

The more affordable EpiPen alternative CVS

Jeanette Perea 2017-01-11
img

President-elect Donald Trump went after drug makers and sent biotech stocks plummeting after calling the drug industry disastrous during his first press conference since the election.

We have to create new bidding procedures for the drug industry, because they re getting away with murder, pharma, Trump said.

Pharma has a lot of lobbies, a lot of lobbyists, a lot of power.

The pledge to overhaul Big Pharma isn t exactly a new one.

During his campaign, Trump promised to crack down on high drug prices and endorsed the idea of having Medicare negotiate drug pricing—a position that has in the past garnered Democratic support and Republican opposition.

After Trump s remarks, the Nasdaq Biotechnology Index fell by more than 3 percent.

Thomas Brazier 2016-08-25
img

Sarah Jessica Parker has cut ties with Mylan, the company that makes EpiPen, after it was criticized for raising the price of the life-saving allergy product by 400 percent.

I m left disappointed, saddened and deeply concerned by Mylan s actions, Parker wrote on Instagram.

I do not condone this decision and I have ended my relationship with Mylan as a direct result of it.

Sarah Jessica Parker became a paid spokesperson for Mylan in May of this year and spoke about her son s life-threatening allergy on behalf of Mylan s Anaphylaxis for Reel campaign.

Parker appeared on TV shows like The View, The Doctors, and Access Hollywood to talk about her son s peanut allergy.

Gizmodo was the first to report on Tuesday that Parker s role as a paid spokesperson for Mylan didn t always include a disclaimer that she was speaking on behalf of the company.

Eric Erikson 2016-10-28
img

Pharmaceutical company Kaléo will offer up an alternative epinephrine auto-injector to Mylan s EpiPen starting in 2017, the company announced this week.

Though Auvi-Q s 2017 price has yet to be set, Kaléo s drug-pricing track record is similar to Mylan s. In the past few years, Kaléo has increased the price of a device used to reverse deadly opioid overdoses by more than 650 percent, in fact.

And, just like Mylan, Turing, and others, Kaléo claimed that costumer assistance programs and discounts would keep high list prices from affecting patients—even though those high list prices can still help drive up overall costs of healthcare.

In an e-mail exchange with Ars, Mark Herzog, vice president of corporate affairs for Kaléo, would not answer direct questions about whether the company would help bring down the inflated costs of epinephrine auto-injectors.

Instead, Herzog noted that the company is working to engage with various stakeholders, including wholesalers, insurance companies, and pharmacy benefit managers, to implement a comprehensive access program for Auvi-Q.

The company s intention, he added, is that any patient who needs an epinephrine auto-injector, regardless of insurance coverage, should have affordable access to Auvi-Q.

Trisha Lewis 2016-08-29
img

Netherlands-based pharmaceutical company Mylan has announced plans to launch its first generic EpiPen.

But at a cost of $300—which is half of the branded product s list price—it s still a heap of money for this critically important medicine.

Mylan is taking a lot of heat these days for boosting the price of its EpiPen by more than 400 percent.

Just eight years ago the auto-injection epinephrine pens, which are used to stave off the effects of potentially life-threatening allergic reactions, were priced at just $100 per pack.

Today the branded product costs about $600.

The company has subsequently been accused of price gouging, attracting the ire of consumers, lawmakers, doctors, and at least one disgruntled celebrity endorser.